Person: YÜCESAN, EMRAH
93 results
Search Results
Now showing 1 - 10 of 93
Publication Metadata only Expression analysis of apoptosis related genes in human hippocampal sclerosis(2011-12-03T00:00:00Z) Yücesan, Emrah; YÜCESAN, EMRAHPublication Metadata only DİRENÇLİ NÖBETLER VE KOGNİTİF YIKIM İLE SEYREDEN NADİR BİR METABOLİK-GENETİK NEDEN: SEREBRAL FOLİNİK ASİT EKSİKLİĞİ(2022-05-29T00:00:00Z) Gezegen, Haşim; Süsgün, Seda; Kesim, Yeşim; Salman, Barış; Yücesan, Emrah; Khalilov, Dovlat; Şirin İnan, Nermin Görkem; Gökçay, Gülden Fatma; Baykal, Betül; Uğur İşeri, Sibel Aylin; Bebek, Nerses; SÜSGÜN, SEDA; YÜCESAN, EMRAHPublication Metadata only Nano- and Micro-Encapsulation Techniques and Applications(2021-01-01T00:00:00Z) Göncü, Beyza Servet; Yücesan, Emrah; GÖNCÜ, BEYZA SERVET; YÜCESAN, EMRAHMicroencapsulation has been the most frequently used technique for several different disciplines such as cell-based therapies and/or transplantation. Technology is based on the idea of combining and coating material or isolating it from an external source. Microencapsulation may be performed with different materials and, among natural biocompatible materials, alginate-based microencapsulation technique is the most appropriate material for microencapsulation. The structural components of alginate materials are the derivatives of alginic acid, which is found in brown algae as an intercellular gel matrix. This alginate is preferred for clinical applications due to its safety in human studies. Therefore, the choice and the combined system need to be carefully optimized to achieve biocompatible application through cell microencapsulation especially for long term. Specifications of alginate such as primary source, isolation process, viscosity, and purity contribute to improve its biocompatibility. Clinically, cell microencapsulation is the major contribution to the field of transplantation by its technique and additionally provides local immune isolation. This chapter discusses the potential benefits of clinically suitable alginates and their applications. This promising technology may highlight its considerable potential for patients that require transplantation and/or replacement therapy in the future.Publication Open Access Parathyroid allotransplantation in rabbits without cultivation.(2014-01-15) CAN, I; YUCESAN, E; Aysan, E; SAYITOGLU, M; OZBEK, U; ERCIVAN, M; ATASOY, H; BUYUKPINARBASILI, NUR; MUSLUMANOGLU, M; AYŞAN, MUSTAFA ERHAN; YÜCESAN, EMRAH; BÜYÜKPINARBAŞILI, NURPermanent hypoparathyroidism is a serious clinical situation. Allotransplantation of the parathyroid cells is relatively new approach to treatment. Non-cultivated allotransplantation in rabbits is not tried before. In this research parathyroidectomy was performed in six female New Zealand white rabbits. After division of surgically removed tissues into two, cryopreservation after cell isolation was done. Non-cultivated cross allotransplantation was performed under immunosuppression. Serum calcium and phosphorus levels were observed 15 days and histopathological analyses of the transplanted parathyroid tissues were studied. Significant changes in serum calcium and phosphorus levels during the experiment were observed (p=0.001 for both). Calcium levels which were significantly dropped to 6.66±0.7 mg/dL after parathyroidectomy and progressively increased up to 15.98±1.25 mg/dL at the end of the experiment (p=0.004). Phosphorus levels which were increased to 9.38±0.63 mg/dL after parathyroidectomy and stabilized to 4.46±1.06 mg/dL at the end of the experiment (p=0.007). All allotransplanted parathyroid tissues showed normal tissue architecture without evidence of cellular rejection. In conclusion allotransplantation of the parathyroid tissues without cultivation may be considered as an alternative and safe approach for the treatment of permanent hypoparathyroidism.Publication Metadata only Expanding Clinical Phenotype of TRAPPC12-Related Childhood Encephalopathy: Two Cases and Review of Literature.(2020-05-05T00:00:00Z) Aslanger, AD; Goncu, B; Demiral, E; Sonmez-Sahin, S; Guler, S; Yucesan, Emrah; Iscan, A; Saltik, S; Yesil, G; GÖNCÜ, BEYZA SERVET; YÜCESAN, EMRAHPublication Metadata only Tıbbi Genetiğin Esasları(2014-06-01T00:00:00Z) Yücesan, Emrah; YÜCESAN, EMRAHPublication Metadata only Screening LGI1 in a cohort of 26 lateral temporal lobe epilepsy patients with auditory aura from Turkey detects a novel de novo mutation.(2016-02-01T00:00:00Z) Kesim, YF; Uzun, GA; Yucesan, Emrah; Tuncer, FN; Ozdemir, O; Bebek, N; Ozbek, U; Iseri, SA; Baykan, B; YÜCESAN, EMRAHPublication Metadata only Evaluation of miR-145 and miR-146a as potential biomarkers for diagnosis of Myelodysplastic Syndrome(2022-06-01T00:00:00Z) Süsgün, Seda; Baykara, Onur; Yücesan, Emrah; Kuru, Rahiye Dilhan; Aslaneli Çakmak, Başak; Yabacı Tak, Ayşegül; Öngören, Şeniz; Deviren, Ayhan; Argüden, Yelda; SÜSGÜN, SEDA; YÜCESAN, EMRAH; YABACI TAK, AYŞEGÜLPublication Metadata only Paratiroit Hücre İzolasyonunda Enzimatik ve Mekanik İzolasyon Yöntemlerinin Karşılaştırılması(2018-05-04T00:00:00Z) Yücesan, Emrah; GÖNCÜ, BEYZA SERVET; YÜCESAN, EMRAHPublication Metadata only Identification and functional characterization of a novel homozygous mutation in KCNMA1 encoding voltage and calcium sensitive potassium channel is associated with dyskinesia, epilepsy, intellectual disability, cerebellar and corticospinal tract atrophy(2020-12-01T00:00:00Z) Servet Göncü, Beyza; Aslanger, Ayça Dilruba; Özgül, Cemil; Hasanoğlu, Sevde; Yeşil Sayın, Gözde; YÜCESAN, EMRAH; GÖNCÜ, BEYZA SERVETIntroduction: KCNMA1 encodes, the alpha subunit of the voltage, and calcium-sensitive potassium channel, predominantly expressed in the central nervous system. Therefore abnormal function in this gene may occur neurological conditions.Materials and Methods: We report 15-year-old patient who was born at term with healthy conditions. Motor signals were delayed, and also seizures started at the age of 18 months. EEG revealed generalized spike-wave activities. Brain MRI performed, atrophy of the cerebellum was detected. Recent clinical examination; contractures on the large joints, and dyskinetic tremor. Whole exome sequencing (WES) was performed and in-slico analyses were conducted. MCF7 and 293T cells transfected with either wild-type or mutant expression vectors. Cellular distribution was determined by immunofluorescence. Functional analysis was performed using electrophysiological approach based on whole-cell patch-clamp.Results: WES revealed homozygous variation (NM_001161352.1:c.1372C>T, p.Arg458Ter). The variant was not observed in publicly available or in-house databases. Immunofluorescent staining revealed that novel variant is not interfering with the synthesis of KCNMA1 however mutation exhibit dominant-negative effect on cell viability when compared to wild-type. 293T and MCF7 cells transfected with homozygous p.Arg458Ter mutation showed markedly increased KCNMA1 currents compared to controls on patch-clamp recording, and these data support loss-of-function effect of all KCNMA1 mutants.Conclusions: Herein we report a 15-year old boy who has neurological conditions. A novel homozygous stop-gain mutation detected by WES and confirmed by conventional sequencing. Afterward, functional characterization was conducted using two step-approach, immunostaining to detect subcellular effect of the variation and patch-clamp to detect a difference between mutant vs. wild-type of the protein. Homozygous mutation was considered as causative for this clinical condition. This study was supported by Bezmialem Vakif University, Scientific Research Projects Unit, Project No:2.2019/7.